Today: November 23, 2017, 7:38 pm
Organizations & Institutions

Drug Manufacturers Pay European Key Opinion Leaders €153-€283 Per Hour on Average

Cutting Edge Information, LLC - We answer questions that no one else can.
Cutting Edge Information, LLC - We answer questions that no one else can.
Regulatory Scrutiny in Europe and U.S. Driving Standardization of Compensation Tracking 2014-08-01 17:03:14
Research Triangle Park, NC – A new study of European fair-market value benchmarks found that drug manufacturers spend between €153 and €283 for a typical key opinion leader (KOL) engagement in Europe, according to Cutting Edge Information.

Payments vary by company size, according to Cutting Edge Information’s data. The study found that biotechnology companies pay European thought leaders anywhere between €50 and €250 per hour, at an average rate of €153. By contrast, large pharmaceutical companies’ payments range between €75 and €600 per hour, at an average rate of €283.

The study, “Determining European KOL Compensation: Fair-Market Value Benchmarks,” details the current trends affecting physician compensation in Europe and provides guidelines for thought leader management teams to set thought leader compensation benchmarks that are competitive and justified.

“KOL payments in Europe have been coming under increasingly intense scrutiny,” said Elio Evangelista, director of research at Cutting Edge Information. “As companies respond to greater regulation of KOL compensation in Europe, we’re seeing a gradual decline and leveling-off of hourly rates.”

A similar trend occurred in the United States as KOL compensation faced greater regulatory scrutiny. Once drug manufacturers started to focus on what they spend for KOL activities, hourly rates declined and became more consistent across companies of differing sizes. Europe is following a similar pattern, Evangelista said.

Already, the Association of the British Pharmaceutical Industry will require disclosure of physician payments for member companies by 2013. Fees requiring disclosure include those for consulting, writing, advisory board participation or speaking at public meetings. Travel and accommodation costs will also be disclosed. Drug manufacturers expect more scrutiny of thought leader compensation from the EMA and country-level regulatory bodies.

“Determining European KOL Compensation: Fair-Market Value Benchmarks” includes benchmark metrics for thought leader compensation and key opinion leader payments. The report includes strategic recommendations designed to help medical affairs, clinical development, legal and compliance executives to:

• Build a comprehensive thought leader management database.
• Calculate fair-market value and develop physician fee schedules.
• Build relationships with clinical and commercial key opinion leaders.

More information about medical affairs strategy and key opinion leader relationships and thought leaders compensation is available at ...

Elio Evangelista
+1 919-403-6583

Press Information
Cutting Edge Information, LLC
68 TW Alexander Drive
Research Triangle Park, NC 27709

Chris Inks
Head of Operations

Published by
Chris Inks

# 370 Words
Related Articles
More From Organizations & Institutions
UN/CEFACT Single Window Conference to Address Risks [..]
Geneva, October 19, 2017 – Global trade facilitation experts will gather in Geneva, Switzerland, October 30 and 31 for the [..]
Invacare modernise the TDX SP2 powerchair base
Global brand leader Invacare has refreshed its TDX SP2 powerchair base making it even more desirable - thanks to its [..]
Empire Court's Annual Sponsored Brunch at Ronald [..]
Empire Court is all set to participate in the “Meals from the Heart” Dinner/Brunch Program which they have participated in [..]
King Hamid launches new initiative in light [..]
In light of the study by GTR (Global Transparency Report) King Hamid of Bahrain has launched new programs aimed at [..]
Analysis of GTR study on King Hamid [..]
The surprising results of the new GTR study calls for deeper analysis and why Bahrain’s King Hamid made it to [..]

Disclaimer: If you have any questions regarding information in this press release please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims the content included in this release.